Regeneron Pharmaceuticals' Profit After Tax rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
Regeneron Pharmaceuticals' Profit After Tax amounted to $1.5 billion in Q3 2025, which was up 4.92% from $1.4 billion recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Profit After Tax registered a high of $3.1 billion during Q2 2021, and its lowest value of $722.0 million during Q1 2024.
In the last 3 years, Regeneron Pharmaceuticals' Profit After Tax had a median value of $1.0 billion in 2023 and averaged $1.1 billion.
Per our database at Business Quant, Regeneron Pharmaceuticals' Profit After Tax spiked by 245.36% in 2021 and then slumped by 72.50% in 2022.
Regeneron Pharmaceuticals' Profit After Tax (Quarterly) stood at $2.2 billion in 2021, then crashed by 46.29% to $1.2 billion in 2022, then decreased by 3.13% to $1.2 billion in 2023, then decreased by 20.86% to $917.7 million in 2024, then increased by 8.91% to $1.5 billion in 2025.
Its Profit After Tax stands at $1.5 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $808.7 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value